Patents by Inventor Ralph Adams

Ralph Adams has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11344639
    Abstract: Provided herein are novel 10Fn3 domains which specifically bind to PD-L1, as well as imaging agents based on the same for diagnostics.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: May 31, 2022
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Paul E. Morin, David Donnelly, Dasa Lipovsek, Jochem Gokemeijer, Maria Jure-Kunkel, David Fabrizio, Martin C. Wright, Douglas Dischino, Samuel J. Bonacorsi, Jr., Ralph Adam Smith, Virginie Lafont, Daniel Cohen, David K. Leung
  • Publication number: 20220089705
    Abstract: This invention is in the area of improved anti-aP2 antibodies and antigen binding agents, and compositions thereof, which target the lipid chaperone aP2/FABP4 (referred to as “aP2”) for use in treating disorders such as diabetes, obesity, cardiovascular disease, fatty liver disease, and/or cancer, among others. In one aspect, improved treatments for aP2 mediated disorders are disclosed in which serum aP2 is targeted and the biological activity of aP2 is neutralized or modulated using low-binding affinity aP2 monoclonal antibodies, providing lower fasting blood glucose levels, improved systemic glucose metabolism, increased systemic insulin sensitivity, reduced fat mass, reduced liver steatosis, reduced cardiovascular disease and/or a reduced risk of developing cardiovascular disease.
    Type: Application
    Filed: May 21, 2021
    Publication date: March 24, 2022
    Applicant: President and Fellows of Harvard College
    Inventors: Gökhan S. Hotamisligil, Mehmet F. Burak, Feyza Engin, Scott B. Widenmaier, Karen Inouye, Elisabeth Helen Roberts, Adrian Richard Moore, Carl Brendan Doyle, Ralph Adams, Karine Jeannine Madeleine Hervé, Shauna Mhairi Wales, Kerry Louise Tyson
  • Publication number: 20220073581
    Abstract: The present invention provides antibodies comprising a variable (V) domain and an insert polypeptide, wherein the insert polypeptide is within the framework 3 region of the V domain.
    Type: Application
    Filed: July 10, 2019
    Publication date: March 10, 2022
    Inventors: Ralph Adams, Terence Seward Baker, Xiaofeng Liu
  • Patent number: 11261242
    Abstract: The present invention relates to antibodies binding alpha synuclein and fragments thereof capable of binding alpha synuclein as a monomer and in fibrils and preventing alpha synuclein aggregation induced by alpha synuclein fibrils. The antibodies of the present invention are for use in the treatment of alpha synucleinopathies, including Parkinson's disease.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: March 1, 2022
    Assignee: UCB BIOPHARMA SRL
    Inventors: Ralph Adams, Patrick Downey, Terence Seward Baker, Kerry Louise Tyson, Lorenzo De Lichtervelde, Daniel John Lightwood, David James McMillan
  • Publication number: 20220001040
    Abstract: Provided herein are novel 10Fn3 domains which specifically bind to PD-L1, as well as imaging agents based on the same for diagnostics.
    Type: Application
    Filed: September 23, 2021
    Publication date: January 6, 2022
    Inventors: Paul E. MORIN, David DONNELLY, Dasa LIPOVSEK, Jochem GOKEMEIJER, Maria N. JURE-KUNKEL, David FABRIZIO, Martin C. WRIGHT, Douglas DISCHINO, Samuel J. BONACORSI, JR., Ralph Adam SMITH, Virginie LAFONT, Daniel COHEN
  • Patent number: 11214627
    Abstract: The present invention relates to the area of improved anti-IgE antibodies and antigen binding agents, and compositions thereof, which target IgE, for instance: for use in treating disorders caused by IgE (such as allergic responses, or certain autoimmune responses); and, in particular, disorders caused by the interaction of IgE with the Fc?RI receptor. In particular, this invention relates to improved anti-IgE antibodies and antigen binding agents related to novel mutants of omalizumab (Xolair®). The improved anti-IgE antibodies and antigen binding agents of the invention may have improved affinity for IgE and/or an improved interaction with the C?2 domain of IgE and/or an improved modified epitope on IgE (for instance further involving the C?2 domain of IgE) and/or the ability to disassociate IgE from the Fc?RI receptor for instance at pharmaceutically-relevant concentrations.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: January 4, 2022
    Assignee: UCB BIOPHARMA SRL
    Inventors: Ralph Adams, Thomas Allen Ceska, Anna Marie Davies, Alistair James Henry, Xiaofeng Liu, James Michael McDonnell, Brian John Sutton, Marta Katarzyna Westwood
  • Patent number: 11173219
    Abstract: Provided herein are novel 10Fn3 domains which specifically bind to PD-L1, as well as imaging agents based on the same for diagnostics.
    Type: Grant
    Filed: July 24, 2019
    Date of Patent: November 16, 2021
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Paul E. Morin, David Donnelly, Dasa Lipovsek, Jochem Gokemeijer, Maria Jure-Kunkel, David Fabrizio, Martin C. Wright, Douglas Dischino, Samuel J. Bonacorsi, Jr., Ralph Adam Smith, Virginie LaFont, Daniel Cohen
  • Publication number: 20210334905
    Abstract: Methods, computer-readable media, software, and apparatuses may determine, for a geographic region and based on geolocation data, a plurality of sub-regions, where each sub-region of the plurality of sub-regions may include real properties with a shared profile. The system may associate, with each sub-region, a collection of coordinate pairs, where each coordinate pair comprises a latitude and a longitude, and the collection describes a boundary of a geometric shape corresponding to the sub-region. The system may associate, with the geographic region, geometric shapes corresponding to the plurality of sub-regions. The system may associate, with each geometric shape, a rating factor for the real properties located within the sub-region corresponding to the geometric shape. The system may store the geometric shapes and rating factors, and may generate, based on the rating factor and for the real properties located within the sub-region, an output, and provide the generated output.
    Type: Application
    Filed: April 24, 2020
    Publication date: October 28, 2021
    Applicants: Allstate Insurance Company, Allstate Insurance Company
    Inventors: Ralph Adam Benjamin Tyner, Jonathan Fesenmeyer, Lauren Ugulini, John Lower, Analini Shetty, Darius Tallat-Kelpsa, David Robert McNulty, Michelle Ann Wagner
  • Publication number: 20210309734
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Application
    Filed: December 15, 2020
    Publication date: October 7, 2021
    Inventors: Ralph Adams, Terence Seward Baker, Alastair David Griffiths Lawson
  • Publication number: 20210301012
    Abstract: The invention is in the field of protein:protein interactions, in particular the stabilisation of protein:protein interactions. Binding proteins are provided for stabilising the interactions, together with compositions comprising the binding proteins. Methods using the binding proteins are also provided, including targeting of cells and also medical uses.
    Type: Application
    Filed: October 23, 2017
    Publication date: September 30, 2021
    Inventors: Michael John Wright, Ralph Adams, Rebecca Burnley, Anna Ettorre
  • Patent number: 11091542
    Abstract: The invention relates to antibody molecules having specificity for TNF alpha, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: August 17, 2021
    Assignee: UCB BIOPHARMA SRL
    Inventors: Ralph Adams, Pallavi Bhatta, Emma Dave, Sam Philip Heywood, David Paul Humphreys, Diane Marshall, Daniel John Lightwood
  • Patent number: 11068985
    Abstract: Methods, computer-readable media, systems and apparatuses for determining and implementing dynamic usage-based insurance policies are presented. A cost per day and a cost per mile associated with the dynamic usage-based insurance policy may be determined. The cost per mile may be computed independently for each of a plurality of road segments comprising a trip based on a time of day that the vehicle traveled each road segment, a road type associated with each road segment. The cost per mile of each road segment of the driving trip may further include whether or not hard braking or hard cornering events were encountered during a specified cumulative driving distance that may include, at least a portion, of a plurality of driving trips. The cost per mile for each of the plurality of driving trips may be adjusted once a threshold distance has been traveled by the vehicle based on the number of hard braking events and hard cornering events occurred during that distance.
    Type: Grant
    Filed: July 16, 2019
    Date of Patent: July 20, 2021
    Assignee: Allstate Insurance Company
    Inventors: Christine L. Bischoff, Dana Ferguson, Eric Huls, Grady Irey, William Polisson, Caryl M. Styrsky, Ralph Adam Benjamin Tyner, Meg G. Walters
  • Publication number: 20210166780
    Abstract: The present invention provides a method for generation of multi-domain proteins, more particular antibodies, with an improved native state colloidal stability.
    Type: Application
    Filed: June 5, 2019
    Publication date: June 3, 2021
    Inventors: Ralph ADAMS, James HEADS, Sebastian KELM, Alastair David Griffiths LAWSON
  • Patent number: 11014979
    Abstract: This invention is in the area of improved anti-aP2 antibodies and antigen binding agents, and compositions thereof, which target the lipid chaperone aP2/FABP4 (referred to as “aP2”) for use in treating disorders such as diabetes, obesity, cardiovascular disease, fatty liver disease, and/or cancer, among others. In one aspect, improved treatments for aP2 mediated disorders are disclosed in which serum aP2 is targeted and the biological activity of aP2 is neutralized or modulated using low-binding affinity aP2 monoclonal antibodies, providing lower fasting blood glucose levels, improved systemic glucose metabolism, increased systemic insulin sensitivity, reduced fat mass, reduced liver steatosis, reduced cardiovascular disease and/or a reduced risk of developing cardiovascular disease.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: May 25, 2021
    Assignee: President and Fellows of Harvard College
    Inventors: Gökhan S. Hotamisligil, Mehmet F. Burak, Feyza Engin, Scott B. Widenmaier, Elisabeth Helen Roberts, Adrian Richard Moore, Carl Brendan Doyle, Ralph Adams, Karine Jeannine Madeleine Hervé, Shauna Mhairi Wales, Kerry Louise Tyson, Karen Inouye
  • Publication number: 20210107971
    Abstract: The present invention relates to antibodies binding alpha synuclein and fragments thereof capable of binding alpha synuclein as a monomer and in fibrils and preventing alpha synuclein aggregation induced by alpha synuclein fibrils. The antibodies of the present invention are for use in the treatment of alpha synucleinopathies, including Parkinson's disease.
    Type: Application
    Filed: December 13, 2018
    Publication date: April 15, 2021
    Inventors: Ralph ADAMS, Patrick DOWNEY, Terence Seward BAKER, Kerry Louise TYSON, Lorenzo DE LICHTERVELDE, Daniel John LIGHTWOOD, David James MCMILLAN
  • Publication number: 20200291104
    Abstract: The invention relates to antibody molecules having specificity for TNF alpha, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Application
    Filed: December 14, 2016
    Publication date: September 17, 2020
    Inventors: Ralph Adams, Pallavi Bhatta, Emma Dave, Sam Philip Heywood, Dave Paul Humphreys, Diane Marshall, Daniel John Lightwood
  • Publication number: 20200277366
    Abstract: The invention relates to multi-specific antibody molecules having specificity for TNF alpha, IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Application
    Filed: December 14, 2016
    Publication date: September 3, 2020
    Applicant: UCB Biopharma SPRL
    Inventors: Ralph ADAMS, Pallavi BHATTA, Emma DAVE, Sam Philip HEYWOOD, David Taul HUMPHERYS, Diane MARSHALL, Stevan Graham SHAW, Daniel John LIGHTWOOD
  • Publication number: 20200157204
    Abstract: The present invention provides an antibody of the class IgG4 comprising at least one heavy chain which comprises a CH1 domain and a hinge region, wherein in each heavy chain: a. the inter-chain cysteine at position 127, numbered according to the Kabat numbering system, in the CH1 domain is substituted with another amino acid; and b. one or more of the amino acids positioned in the upper hinge region is substituted with cysteine.
    Type: Application
    Filed: December 17, 2019
    Publication date: May 21, 2020
    Inventors: David Paul Humphreys, Ralph Adams, James Heads, Shirley Jane Peters
  • Patent number: 10562966
    Abstract: The present invention provides an antibody of the class IgG4 comprising at least one heavy chain which comprises a CH1 domain and a hinge region, wherein in each heavy chain: a. the inter-chain cysteine at position 127, numbered according to the Kabat numbering system, in the CH1 domain is substituted with another amino acid; and b. one or more of the amino acids positioned in the upper hinge region is substituted with cysteine.
    Type: Grant
    Filed: August 19, 2011
    Date of Patent: February 18, 2020
    Assignee: UCB BIOPHARMA SPRL
    Inventors: David Paul Humphreys, Shirley Jane Peters, Ralph Adams, James Heads
  • Publication number: 20200048372
    Abstract: A multivalent antibody fusion protein which comprises an immunoglobulin moiety, for example a Fab or Fab? fragment, with a first specificity for an antigen of interest, and further comprises two single domain antibodies (dAb) with specificity for a second antigen of interest, wherein the two single domain antibodies are linked by a disulfide bond. There is also provided particular dual specificity antibody fusion proteins comprising a Fab or Fab? fragment and one or more single domain antibodies which may be stabilised by a disulfide bond therebetween.
    Type: Application
    Filed: July 11, 2019
    Publication date: February 13, 2020
    Inventors: Ralph Adams, Laura Hancock, Sam Philip Heywood